59 patients with non-small cell lung cancer were treated with cisplatin (60 mg/m2) on day 1 and etoposide (60 mg/m2) on days 1-5. The results of the treatment were evaluated after 4th course. Remissions were seen in 27 patients, 17 patients had stabilization and 15-progression. The response rate in stages I and II was 70%, in stage III-40% and in stage IV-23%. In squamous cell carcinoma the response rate was 55%, in large cell carcinoma-25% and in adenocarcinoma-12%.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Moving towards single fraction peripheral lung stereotactic body radiation therapy: patient care during and after the global COVID-19 pandemic.
Lung Cancer Manag
July 2024
Department of Radiation Oncology, University of Manitoba, Winnipeg, MB, Canada.
Single-fraction stereotactic body radiation therapy (SF-SBRT) for peripheral lung tumors was reviewed. Medically inoperable peripheral lung tumors eligible for SF-SBRT 34 Gray were treated. Patient characteristics, treatment and toxicity parameters were retrospectively collected, and toxicities were evaluated.
View Article and Find Full Text PDFMolecular and therapeutic insight into ER Stress signaling in NSCLC.
J Drug Target
January 2025
Department of Biotechnology and Bioengineering, Institute of Advanced Research, Gandhinagar, India.
Endoplasmic Reticulum (ER) stress is intricately involved in cancer development, progression and response to chemotherapy. ER stress related genes might play an important role in predicting the prognosis in lung adenocarcinoma patients and may be manipulated to improve the treatment outcome and overall survival rate. In this review, we analyzed the contribution of the three major ER stress pathways-IRE1, ATF6, and PERK-in lung cancer pathogenesis via modulation of tumor microenvironment (TME) and processes as metastasis, angiogenesis, apoptosis and N-glycosylation.
View Article and Find Full Text PDFVirtual bronchoscopic navigation and guided radial endobronchial ultrasound for peripheral pulmonary lesions: harmonizing modalities to optimize accuracy.
Monaldi Arch Chest Dis
January 2025
Department of Pulmonary Medicine, Vallabhbhai Patel Chest Institute, University of Delhi, New Delhi.
Peripheral pulmonary lesions (PPLs) present a significant diagnostic challenge due to their location beyond the reach of traditional bronchoscopy. With lung cancer being the leading cause of cancer-related mortality worldwide, accurate and early diagnosis of PPLs is crucial. Virtual bronchoscopic navigation (VBN) combined with radial endobronchial ultrasound (R-EBUS) has emerged as a promising technique to enhance the diagnostic yield for these lesions.
View Article and Find Full Text PDFFirst-line treatment for advanced or metastatic EGFR mutation-positive non-squamous non-small cell lung cancer: a network meta-analysis.
Front Oncol
January 2025
Department of Oncology, Bishan Hospital of Chongqing Medical University, Chongqing, China.
Background: Several head-to-head meta-analyses have compared the efficacy and safety of different first-line treatments in patients with EGFR mutation-positive (M+) advanced or metastatic non-squamous non-small cell lung cancer (nsq-NSCLC). However, there is a lack of comprehensive evaluation encompassing multiple treatment strategies. Our objective is to conduct a network meta-analysis that includes various treatment modalities, enabling both direct and indirect comparisons for a more thorough assessment.
View Article and Find Full Text PDFBackground: Rearranged during transfection () fusions represent a distinct molecular subset of non-small cell lung cancer (NSCLC) with targeted therapeutic potential. Selpercatinib, a highly selective inhibitor, has demonstrated efficacy in various solid tumors harboring alterations. Here, we present a case highlighting the use and clinical outcomes of selpercatinib in a patient diagnosed with advanced lung adenocarcinoma harboring a fusion.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!